US2006258667A1PendingUtilityA1

Method for improving respiratory function and inhibiting muscular degeneration

59
Individually held — no corporate assignee on recordPriority: Mar 14, 2000Filed: May 5, 2006Published: Nov 16, 2006
Est. expiryMar 14, 2020(expired)· nominal 20-yr term from priority
Inventors:Yang Teng
A61K 45/06A61K 31/137A61K 31/506
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides a method for improving respiratory function and inhibiting muscular degeneration (e.g., dystrophy and atrophy). Alternative embodiments of the invention provide a method of inhibiting motor neuron apoptosis and the subsequent muscular degeneration associated with the denervation of muscular tissue resulting from neuron death.

Claims

exact text as granted — not AI-modified
1 . A method of improving respiratory function in an individual with abnormal respiratory function comprising administering an agent selected from the group consisting of: a serotonin (5HT) receptor type 1A agonist and a β2-adrenergic agonist.  
     
     
         2 . The method of  claim 1  wherein the individual with abnormal respiratroy function is afflicted with ALS.  
     
     
         3 . The method of  claim 1  wherein the individual with abnormal respiratory function suffers from a spinal cord injury.  
     
     
         4 . The method of  claim 1  wherein the serotonin (5HT) receptor type 1A agonist is selected from the group consisting of 8-OH-DPAT and buspirone.  
     
     
         5 . The method of  claim 1  wherein the β2-adrenergic agonist is selected from the group consisting of clenbuterol and salbutanol.  
     
     
         6 . A method of inhibiting motor neuron apoptosis in an individual comprising administering a β2-adrenergic agonist selected from the group consisting of clenbuterol and salbutanol.  
     
     
         7 . The method of  claim 6  wherein the individual in whom motor neuron apoptosis is inhibited has a disorder selected from the group consisting of: ALS and spinal cord injury.  
     
     
         8 . A method of inhibiting muscular degeneration in an individual comprising administering an agent selected from the group consisting of: a serotonin (5HT) receptor type 1A agonist and a β2-adrenergic agonist.  
     
     
         9 . The method of  claim 8  wherein the individual is afflicted with ALS.  
     
     
         10 . The method of  claim 8  wherein the individual suffers from a spinal cord injury.  
     
     
         11 . The method of  claim 8  wherein the serotonin (5HT) receptor type 1A agonist is selected from the group consisting of 8-OH-DPAT and buspirone.  
     
     
         12 . The method of  claim 8  wherein the β2-adrenergic agonist is selectd from the group consisting of clenbuterol and salbutanol.  
     
     
         13 . A method of inhibiting denervation of muscle in an individual afflicted with ALS comprising administering a β2-adrenergic agonist selected from the group consisting of clenbuterol and salbutanol.  
     
     
         14 . A method of inhibiting denervation of muscle in an individuals suffering from a spinal cord injury comprising administering a β2-adrenergic agonist selected from the group consisting of clenbuterol and salbutanol.  
     
     
         15 . A method of preventing respiratory abnormalities in an individual afflicted with ALS comprising administering a serotonin (5HT) receptor type 1A agonist in combination with a β2-adrenergic agonist.  
     
     
         16 . A method of preventing muscular degeneration in an individual afflicted with ALS comprising administering a serotonin (5HT) receptor type 1A agonist in combination with a β2-adrenergic agonist.

Join the waitlist — get patent alerts

Track US2006258667A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.